Dr. Jonathan Sackner-Bernstein
MD, PhD, FRCPE
Sackner-Bernstein conducted the first study to estimate the amount of dopamine free in the cytosol of the dopaminergic neurons in people with Parkinson’s. While confirming that tissue levels of dopamine are markedly reduced, statistical adjustments for the loss of neurons, axons and intracellular vesicles demonstrated that free dopamine levels trended higher in the caudate and were significantly elevated in the putamen. In parallel, multiple preclinical studies showed that the use of a drug to reduce dopamine improved biology and function. The data suggest that the neurons that drive Parkinson’s experience the disease as a state of dopamine excess, not deficiency, relevant because of the potential for dopamine’s breakdown products causing neuronal toxicity. Sackner-Bernstein launched a company to test such a drug treatment strategy in PD.
Videos
“Why I am optimistic that we might have a Silver Bullet for PD” – update by Dr. Sackner-Bernstein – UPDATE
Jonathan Sackner-Bernstein is aiming to transform the treatment of Parkinson’s Disease (PD). First, he discovered that the brain cells (dopaminergic neurons) in Parkinson’s patients are exposed to excess dopamine, reaching toxic levels. Next, he identified a drug that reverses disease pathology by reducing dopamine levels in 10 studies using laboratory models of PD. Today’s session focuses on Dr. Sackner-Bernstein’s most recent progress.
July 1, 2025 – Video length 34:17
A Shocking New Treatment for Parkinson’s: How LESS Dopamine Could Halt Progression
Could a simple drug intended to treat cancer treatment complications be the next big breakthrough in Parkinson’s Disease treatment? Dr. Michael Hyland, DPT, CEEAA with Parkinson’s Disease Education breaks it down in this video.
March 1, 2025 – Video length 16:58
Redefining Parkinson’s: Dr. Jonathan Sackner-Bernstein on a Novel Approach to Treatment and Reversal
In this insightful episode of the Neuron Regeneration Podcast, we explore a groundbreaking new perspective on Parkinson’s Disease treatment. Dr. Jonathan Sackner-Bernstein, a physician, engineer, and former FDA and DARPA leader, challenges the long-held belief that Parkinson’s is solely a disease of dopamine deficiency.
February 28, 2025 – Video length 42:22
REDUCING Dopamine to Treat Parkinson’s?? – Interview with Dr. Jonathan Sackner-Bernstein, MD
In this exclusive interview, I was honored to sit down with Dr. Jonathan Sackner-Bernstein to discuss his groundbreaking work in the treatment of Parkinson’s Disease. As a leading expert and innovator, Dr. Sackner-Bernstein shares insights into the challenges of current therapies, exciting advancements in research, and the potential for transformative treatments that could improve the lives of millions.
January 29, 2025 – Video length 46:14
“Why I am optimistic that we might now have a Silver Bullet for PD” by Dr Jonathan Sackner-Bernstein
Presentation by Dr Jonathan Sackner-Bernstein, MD, on the topic of “Why I am optimistic that we might now have a Silver Bullet for Parkinson’s”, followed by a Q&A session of almost 50 probing questions from our audience.
June 21, 2024- Video length 1:29:24
Conquering Parkinson’s
In October 2023, Jim McCann and Jonathan Sackner-Bernstein discussed the breakthrough discovery in understanding of and treatment for Parkinson’s Disease.
December 26, 2023 – Video length 9:15
More from Dr. Sackner-Bernstein
Website
No one gets better with Parkinson’s.
Until now.
Starting as one person’s hobby and now as a company focused on the development of dopamine reduction therapy for those with Parkinson’s
Blog
This blog will share questions, ideas, and possibilities. These posts will be based on science and/or reasoning, applying the author’s (Jonathan Sackner-Bernstein) expertise as an engineer, clinician (cardiologist), clinical trialist, regulator, and innovator.
White Paper
NO ONE GETS BETTER WITH PARKINSON’S DISEASE:
UNTIL NOW
Dopamine Reduction Therapy to Conquer Parkinson’s
April, 2024